Delivery Order SPE2DB22D9316-SPE2DB25FYN22
Award Date
2/3/25
Potential Completion Date
2/25/25
Potential Value
$11K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $51,581.80 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB24FPQG7, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military medical facilities. DMS Pharmaceutical...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB procurement program. The contract is for $10,316.36 and covers the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, with a period of performance through July 2, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of the pharmaceutical product TYSABRI 300 MG/15 ML VIAL 15ML. The total potential value of the contract is $10,316.36, with a completion date of January 29, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that provides a range of pharmaceutical and medical supplies to the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $10,316.36 firm fixed-price delivery order covers the supply of Tysabri 300 mg/15 ml vial, with an ultimate completion date of October 31, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $51,581.80, is for the delivery of the pharmaceutical product Tysabri 300 mg/15 ml vial with a completion date of October 16, 2023. DMS Pharmaceutical Group Inc. holds a large Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,547.76 contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,158.18 order is for TYSABRI 300 MG/15 ML VIAL 15ML, a biologic medication. The order has a completion date of July 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the provision of TYSABRI 300 MG/15 ML VIAL 15ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, awarded by the Defense Logistics Agency (DLA), a defense agency, with a ceiling value of $10,316.36 and an ultimate completion date of April 9, 2024. The contract has no set-aside designation. This award is part of a larger indefinite delivery contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $21,051.08 and covers the supply of Tysabri, a 300 mg/15 ml vial medication, with a period of performance through January 27, 2025. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...